BACKGROUND: Hospice brings substantial clinical benefits to dying patients and families but is underutilized by patients dying of hematologic malignancies (HM); nationwide, only 2% of HM patients use hospice. There are 70,000 deaths among U.S. patients with hematologic malignancies yearly. OBJECTIVE: We measured the use and length of stay (LOS) in hospice among patients with HMs at a large academic cancer center. DESIGN: This was a single center retrospective review of adult patients (≥18 years) with lymphoma, leukemia, myelodysplastic syndrome, aplastic anemia, and multiple myeloma referred for hospice. MEASUREMENTS: Information included demographics, transplant, hospice type, LOS, and use of "expanded access" services. RESULTS: Fifty-nine patients were referred to hospice, and 53 utilized hospice services, 25% of 209 HM decedents. Thirty-five received home hospice and 18 used inpatient hospice. The median home hospice LOS was nine days (SD 13) and inpatient hospice six days (SD 10). Nine patients with "expanded access" hospice received only a few blood transfusions, and none received radiation. CONCLUSIONS: HM patients are referred late or never for hospice services. Studies evaluating earlier integration of palliative and hospice care with usual HM care are warranted. We present a one-page negotiation form that we have found useful in negotiations among HM physicians, hospice medical directors, and payers.
BACKGROUND: Hospice brings substantial clinical benefits to dying patients and families but is underutilized by patients dying of hematologic malignancies (HM); nationwide, only 2% of HM patients use hospice. There are 70,000 deaths among U.S. patients with hematologic malignancies yearly. OBJECTIVE: We measured the use and length of stay (LOS) in hospice among patients with HMs at a large academic cancer center. DESIGN: This was a single center retrospective review of adult patients (≥18 years) with lymphoma, leukemia, myelodysplastic syndrome, aplastic anemia, and multiple myeloma referred for hospice. MEASUREMENTS: Information included demographics, transplant, hospice type, LOS, and use of "expanded access" services. RESULTS: Fifty-nine patients were referred to hospice, and 53 utilized hospice services, 25% of 209 HM decedents. Thirty-five received home hospice and 18 used inpatient hospice. The median home hospice LOS was nine days (SD 13) and inpatient hospice six days (SD 10). Nine patients with "expanded access" hospice received only a few blood transfusions, and none received radiation. CONCLUSIONS: HM patients are referred late or never for hospice services. Studies evaluating earlier integration of palliative and hospice care with usual HM care are warranted. We present a one-page negotiation form that we have found useful in negotiations among HM physicians, hospice medical directors, and payers.
Authors: Haifa K Al-Ali; Nadja Jaekel; Christian Junghanss; Georg Maschmeyer; Rainer Krahl; Michael Cross; Gisa Hoppe; Dietger Niederwieser Journal: Leuk Lymphoma Date: 2011-08-24
Authors: Katherine Freund; Michelle T Weckmann; David J Casarett; Kristi Swanson; Mary Kay Brooks; Ann Broderick Journal: J Hosp Med Date: 2011-11-15 Impact factor: 2.960
Authors: William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Thomas J Smith; Sarah Temin; Erin R Alesi; Amy P Abernethy; Tracy A Balboni; Ethan M Basch; Betty R Ferrell; Matt Loscalzo; Diane E Meier; Judith A Paice; Jeffrey M Peppercorn; Mark Somerfield; Ellen Stovall; Jamie H Von Roenn Journal: J Clin Oncol Date: 2012-02-06 Impact factor: 44.544
Authors: Catherine Henckel; Anna Revette; Scott F Huntington; James A Tulsky; Gregory A Abel; Oreofe O Odejide Journal: J Pain Symptom Manage Date: 2020-01-09 Impact factor: 3.612
Authors: Thomas W LeBlanc; Jonathan D O'Donnell; Megan Crowley-Matoka; Michael W Rabow; Cardinale B Smith; Douglas B White; Greer A Tiver; Robert M Arnold; Yael Schenker Journal: J Oncol Pract Date: 2015-03 Impact factor: 3.840
Authors: Winnie S Wang; Joseph D Ma; Sandahl H Nelson; Carolyn Revta; Gary T Buckholz; Carolyn Mulroney; Eric J Roeland Journal: Support Care Cancer Date: 2017-12-28 Impact factor: 3.603
Authors: Rong Wang; Amer M Zeidan; Stephanie Halene; Xiao Xu; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Cary P Gross; Steven D Gore; Xiaomei Ma Journal: J Clin Oncol Date: 2017-08-07 Impact factor: 44.544
Authors: Areej R El-Jawahri; Gregory A Abel; David P Steensma; Thomas W LeBlanc; Amir T Fathi; Timothy A Graubert; Daniel J DeAngelo; Martha Wadleigh; Karen K Ballen; Julia E Foster; Eyal C Attar; Philip C Amrein; Andrew M Brunner; Richard M Stone; Jennifer S Temel Journal: Cancer Date: 2015-04-29 Impact factor: 6.860
Authors: Oreofe O Odejide; Diana Y Salas Coronado; Corey D Watts; Alexi A Wright; Gregory A Abel Journal: J Oncol Pract Date: 2014-10-07 Impact factor: 3.840